An athlete should not infer that a preparation is permitted because its label says no DAC, describes a short duration, or calls it a research product. Anti-doping classification is not a comparison of which version feels milder.
The 2026 WADA Prohibited List includes GHRH and its analogues in section S2, with CJC compounds among the examples. The category is broader than a single spelling or commercial presentation.
Naming does not create permission
A prohibited-class rule cannot be resolved by finding that an exact retail alias is absent from a short example list. The relevant question is the substance's identity and how the applicable rules classify it. Removing a marketing term does not establish an exemption.
Similarly, an uncertain or shorter half-life is not evidence of permission. Pharmacokinetic claims and competition rules are separate issues. This article does not estimate detection windows, propose timing around events or offer a way to avoid testing.
A certificate of analysis also has a different role. It may help characterize a product, but it is not authorization from a sporting body. A clinician's involvement likewise does not automatically settle an athlete's regulatory obligations.
Athletes should use their governing body's current official resources and seek advice through its medical and anti-doping channels before making decisions. Rules can differ by organization, and a future publication should recheck the applicable edition rather than treating a dated summary as permanent.
The broader lesson is to keep three questions separate: what the product contains, whether a clinical use is supported, and whether the sport permits it. A favorable answer to one cannot replace the others. No-DAC wording does not itself establish permission, safety or a clinically useful effect, and a research-oriented article should not imply otherwise.